The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what FDA Peptide Reclassification 2026: What Researchers Want FDA Action Update, January 2026: Approvals, Acceptance, and Clearance NeurologyLive Clinical Neurology News and Neurology Expert Insights GHK Cu Peptide Therapy Brea, CA Orange County